Having demonstrated the capacity of CART cells co-secreting IL6 and IL1 blockers and their safety in mouse model, we initiated a clinical investigation of the safety and efficacy of CART-aIL6/IL1RA for targeting CD19 or BCMA, with 18 patients enrolled, including ALL, CLL, lymphoma and multiple myeloma (MM) as summarized in Table 1. Here, IL6R is linked to lymphoma.